updated 11/2/2004 8:03:34 PM ET 2004-11-03T01:03:34

The Food and Drug Administration warned consumers Tuesday not to buy or use the supplements Actra-Rx or Yilishen because they contain an ingredient that could lower blood pressure to unsafe levels.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The FDA also instructed employees to block imports of the supplements, calling them “dangerous ... and even life-threatening.” The agency said the supplement bears the name Yilishen when it is imported from China and is sold as Actra-Rx within the United States.

Laura Alvey, an FDA spokeswoman, declined further comment, saying the matter is under investigation that may lead to criminal or civil enforcement actions.

When the FDA in March 27, 1998 approved Viagra, the first pill to treat impotence, it warned consumers not to use the drug in combination with products containing nitrates to avoid worrisome lowering of blood pressure.

Because people buy Actra-Rx without a doctor’s prescription, however, consumers receive no such warning.

Actra-Rx and Yilishen are promoted on Web sites as erectile dysfunction treatments that enhance men’s sexual performance, the FDA said.

Despite an all-natural label, Actra-Rx capsules contain prescription strength levels of sildenafil, the active ingredient in Viagra, according to a letter published in the Journal of the American Medical Association.

According to “Sex, Lies and Niagra,” published in the Feb. 4, 2004 issue of JAMA, chemical analyses found an average of 55 milligrams of sildenafil per capsule of Actra-Rx and Niagra Actra-Rx, another name under which the product has been sold.

“The use of such nonprescription substances may present health risks for individuals with contraindications to the use of sildenafil,” wrote the authors.

Follow up testing by the FDA confirmed Actra-Rx contained prescription-strength levels of sildenafil.

The recommended dose for Viagra, produced by Pfizer, is 50 milligrams. Some men take as little as 25 milligrams or as much as 100 milligrams. Last year, Viagra cornered 90 percent of the market for drugs treating sexual dysfunction with sales of $1.14 billion. In the first seven months of 2004, its market share eroded to 76.5 percent and sales totaled $597 million, according to IMS Health statistics.

A spokesman for Los Angeles-based Body Basics declined comment. The company’s voicemail identifies them as manufacturer of Actra-Rx. The company’s Web site continues to advertise Actra-Rx as a “natural sexual enhancer” available in starter kits of 10 pills for $78.99.

In June 2003, Pfizer filed a trademark infringement suit against Body Basics, which had been using the name Niagra to sell the supplement. The federal court, in a consent judgment, barred the company from using that name, said Bryant Haskins, director of corporate media relations at Pfizer.

According to the FDA, the sildenafil in Actra-Rx can interact with certain prescription drugs that contain nitrates or nitrates in illicit substances, significantly lowering blood pressure to unsafe levels.

Men at risk include those with diabetes, high blood pressure, high cholesterol or heart disease. Those individuals use medications that contain nitrates and often suffer erectile dysfunction.

The FDA advised people who have taken Actra-Rx or Yilishen to stop using it and to consult a doctor regarding an alternate erectile dysfunction treatment.

© 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments